Prasugrel overcomes high on-clopidogrel platelet reactivity in the acute phase of acute coronary syndrome and maintains its antiplatelet potency at 30-day follow-up

Cardiology Journal

Volumn 21, Issue 5, 2014, Pages 547-556

  Koziński, Marek ^a   Obońska, Karolina ^a   Stankowska, Katarzyna ^a   Navarese, Eliano Pio ^a   Fabiszak, Tomasz ^a   Stolarek, Wioleta ^a   Kasprzak, Michał ^a   Siller Matula, Jolanta Maria ^b   Rość, Danuta ^a   Kubica, Jacek ^a   De Servi, Stefano ^c  

^a NICOLAUS COPERNICUS UNIVERSITY   (Poland)

^b MEDICAL UNIVERSITY OF VIENNA   (Austria)

^c FONDAZIONE IRCCS POLICLINICO SAN MATTEO   (Italy)

Author keywords

Clopidogrel; High on treatment platelet reactivity; Multiple electrode aggregometry; Prasugrel; VASP assay

Indexed keywords

ABCIXIMAB; ADENOSINE DIPHOSPHATE; CLOPIDOGREL; EPTIFIBATIDE; PRASUGREL; VASODILATOR STIMULATED PHOSPHOPROTEIN; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; CAROTID ARTERY STENTING; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; FLOW CYTOMETRY; HIGH ON CLOPIDOGREL PLATELET REACTIVITY; HUMAN; LOADING DRUG DOSE; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET REACTIVITY; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTOSIS; ADOLESCENT; ANALOGS AND DERIVATIVES; BLOOD; DOSE RESPONSE; DRUG EFFECTS; FOLLOW UP; PROSPECTIVE STUDY; RADIOGRAPHY; THROMBOCYTE; TREATMENT OUTCOME; YOUNG ADULT;

ACUTE CORONARY SYNDROME; ADOLESCENT; ADULT; AGED; BLOOD PLATELETS; CORONARY ANGIOGRAPHY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLATELET AGGREGATION INHIBITORS; PRASUGREL HYDROCHLORIDE; PROSPECTIVE STUDIES; TICLOPIDINE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84904607606     PISSN: 18975593     EISSN: 1898018X     Source Type: Journal    
DOI: 10.5603/CJ.a2014.0026     Document Type: Article

References (30)

1. Tantry US, Bonello L, Aradi D et al. Consensus and future direc­tions on the definition of high on-treatment platelet reactivity to adenosine diphosphate. J Am Coll Cardiol, 2013; 62: 2261-2273.
2. Siller-Matula JM, Delle-Karth G, Lang IM et al. Phenotyping vs. genotyping for prediction of clopidogrel efficacy and safety: The PEGASUS-PCI study. J Thromb Haemost, 2012; 10: 529-542.
3. Aradi D, Komócsi A, Vorobcsuk A et al. Prognostic significance of high on-clopidogrel platelet reactivity after percutaneous coronary intervention: Systematic review and meta-analysis. Am Heart J, 2010; 160: 543-551.
4. Wiviott SD, Braunwald E, McCabe CH et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 2007; 357: 2001-2015.
5. Navarese EP, Verdoia M, Schaffer A et al. Ischaemic and bleeding complications with new, compared to standard, ADP-antagonist regimens in acute coronary syndromes: A meta-analysis of ran­domized trials. QJM, 2011; 104: 561-569.
6. Kozinski M, Bielis L, Wisniewska-Szmyt J et al. Diurnal variation in platelet inhibition by clopidogrel. Platelets, 2011; 22: 579-587.
7. Wijns W, Kolh P, Danchin N et al. Guidelines on myocardial reva­scularization. Eur Heart J, 2010; 31: 2501-2555.
8. Aleil B, Ravanat C, Cazenave JP, Rochoux G, Heitz A, Gachet C. Flow cytometric analysis of intraplatelet VASP phosphorylation for the detection of clopidogrel resistance in patients with ische­mic cardiovascular diseases. J Thromb Haemost, 2005; 3: 85-92.
9. Tóth O, Calatzis A, Penz S, Losonczy H, Siess W. Multiple electro­de aggregometry: A new device to measure platelet aggregation in whole blood. Thromb Haemost, 2006; 96: 781-788.
10. Frere C, Cuisset T, Quilici J et al. ADP-induced platelet aggre­gation and platelet reactivity index VASP are good predictive markers for clinical outcomes in non-ST elevation acute coronary syndrome. Thromb Haemost, 2007; 98: 838-843.
11. Bonello L, Paganelli F, Arpin-Bornet M et al. Vasodilator-stimu­lated phosphoprotein phosphorylation analysis prior to percu­taneous coronary intervention for exclusion of postprocedural major adverse cardiovascular events. J Thromb Haemost, 2007; 5: 1630-1636.
12. Blindt R, Stellbrink K, de Taeye A et al. The significance of vasodilator-stimulated phosphoprotein for risk stratification of stent thrombosis. Thromb Haemost, 2007; 98: 1329-1334.
13. Barragan P, Bouvier JL, Roquebert PO et al. Resistance to thie­nopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphory­lation. Catheter Cardiovasc Interv, 2003; 59: 295-302.
14. Bonello L, Camoin-Jau L, Arques S et al. Adjusted clopidogrel loading doses according to vasodilator-stimulated phosphoprotein phosphorylation index decrease rate of major adverse cardiovascular events in patients with clopidogrel resistance: A multicenter rando­mized prospective study. J Am Coll Cardiol, 2008; 51: 1404-1411.
15. Sibbing D, Braun S, Morath T et al. Platelet reactivity after clopidogrel treatment assessed with point-of-care analysis and early drug-eluting stent thrombosis. J Am Coll Cardiol, 2009; 53: 849-856.
16. El Ghannudi S, Ohlmann P, Meyer N et al. Impact of P2Y12 inhibition by clopidogrel on cardiovascular mortality in unse­lected patients treated by percutaneous coronary angioplasty: A prospective registry. J Am Coll Cardiol Cardiovasc Interv, 2010; 3: 648-656.
17. Jeong YH, Bliden KP, Tantry US, Gurbel PA. High on-treatment platelet reactivity assessed by various platelet function tests: Is the consensus-defined cut-off of VASP-P platelet reactivity index too low? J Thromb Haemost, 2012; 10: 487-489.
18. Siller-Matula JM, Christ G, Lang IM, Delle-Karth G, Huber K, Jilma B. Multiple electrode aggregometry predicts stent thrombosis better than the vasodilator-stimulated phosphoprotein phospho­rylation assay. J Thromb Haemost, 2010; 8: 351-359.
19. Bonello L, Pansieri M, Mancini J et al. High on-treatment platelet reactivity after prasugrel loading dose and cardiovascular events after percutaneous coronary intervention in acute coronary syn­dromes. J Am Coll Cardiol, 2011; 58: 467-473.
20. Michelson AD, Frelinger AL 3rd, Braunwald E et al. Pharmacody­namic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial. Eur Heart J, 2009; 30: 1753-1763.
21. Alexopoulos D, Dimitropoulos G, Davlouros P et al. Prasugrel overcomes high on-clopidogrel platelet reactivity post-stenting more effectively than high-dose (150-mg) clopidogrel: the impor­tance of CYP2C19*2 genotyping. J Am Coll Cardiol Cardiovasc Interv, 2011; 4: 403-410.
22. Alexopoulos D, Galati A, Xanthopoulou I et al. Ticagrelor versus prasugrel in acute coronary syndrome patients with high on­-clopidogrel platelet reactivity following percutaneous coronary intervention: a pharmacodynamic study. J Am Coll Cardiol, 2012; 60: 193-199.
23. Sardella G, Calcagno S, Mancone M et al. Pharmacodynamic effect of switching therapy in patients with high on-treatment platelet reactivity and genotype variation with high clopidogrel Dose versus prasugrel: the RESET GENE trial. Circ Cardiovasc Interv, 2012; 5: 698-704.
24. Alexopoulos D, Theodoropoulos KC, Stavrou EF et al. Prasugrel versus high dose clopidogrel to overcome early high on clopido­grel platelet reactivity in patients with ST elevation myocardial infarction. Cardiovasc Drugs Ther, 2012; 26: 393-400.
25. Bouman HJ, Parlak E, van Werkum JW et al. Which platelet function test is suitable to monitor clopidogrel responsiveness? A pharmacokinetic analysis on the active metabolite of clopidogrel. J Thromb Haemost, 2010; 8: 482-488.
26. Wiviott SD, Trenk D, Frelinger AL et al. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation, 2007; 116: 2923-2932.
27. Angiolillo DJ, Badimon JJ, Saucedo JF et al. A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: Results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. Eur Heart J, 2011; 32: 838-846.
28. Montalescot G, Sideris G, Cohen R et al. Prasugrel compared with high-dose clopidogrel in acute coronary syndrome. The randomised, double-blind ACAPULCO study. Thromb Haemost, 2010; 103: 213-223.
29. Trenk D, Stone GW, Gawaz M et al. A randomized trial of prasu­grel versus clopidogrel in patients with high platelet reactivity on clopidogrel after elective percutaneous coronary intervention with implantation of drug-eluting stents: results of the TRIGGER-PCI (Testing Platelet Reactivity In Patients Undergoing Elective Stent Placement on Clopidogrel to Guide Alternative Therapy With Pra­sugrel) study. J Am Coll Cardiol, 2012; 59: 2159-2164.
30. Kubica A, Kozinski M, Grzesk G, Fabiszak T, Navarese EP, Goch A. Genetic determinants of platelet response to clopidogrel. J Thromb Thrombolysis, 2011; 32: 459-466.